GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Devyser Diagnostics AB (FRA:OL0) » Definitions » Capital Expenditure

Devyser Diagnostics AB (FRA:OL0) Capital Expenditure : €-6.14 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Devyser Diagnostics AB Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Devyser Diagnostics AB's cash flow for capital expenditures for the three months ended in Mar. 2025 was €-1.81 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2025 was €-6.14 Mil.

Devyser Diagnostics AB Capital Expenditure Historical Data

The historical data trend for Devyser Diagnostics AB's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Devyser Diagnostics AB Capital Expenditure Chart

Devyser Diagnostics AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial -0.34 -0.86 -2.35 -2.86 -6.69

Devyser Diagnostics AB Quarterly Data
Dec18 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.44 -0.95 -1.50 -1.89 -1.81

Devyser Diagnostics AB Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Devyser Diagnostics AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Devyser Diagnostics AB (FRA:OL0) » Definitions » Capital Expenditure
Comparable Companies
OSTO:SENZA OSTO:AROC OSTO:IMMNOV NGM:LUMITO XSAT:GEAN NGM:ATANA NGM:LEVBIO OSTO:PROGEN XSAT:SPERM TMO DHR XSWX:LONN IDXX A SHSE:603259 IQV MTD NTRA WAT LH
Traded in Other Exchanges
DVYSR:Sweden
Address
Instrumentvagen 19, Hagersten, SWE, 126 53
Website
https://www.devyser.com
Devyser Diagnostics AB develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. The products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.

Devyser Diagnostics AB Headlines

No Headlines